- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT07797985
To Identify if a COPD Self-management App Can Safety and Appropriately Identify When Patients Are Not on the Best Medication Plan for Their COPD Symptoms and Support Their COPD Management. (mySmartCOPD)
To Explore the Safety and Clinical Efficacy of a Treatment Realignment Algorithm Using Data From a Digital Self-management Application for Patients With COPD
Although COPD cannot be cured, managing COPD can help reduce symptoms control, slows progression of the disease, and may improve the quality of life. Management of COPD becomes less effective when healthcare professionals fail to prescribe appropriate inhaled therapies, due to poor adherence to evidence-based guidelines and underdiagnosis, or when patients fail to adhere to prescribed treatment regimens.
my mhealth has developed an app called myCOPD to allow patients to record their COPD symptoms and medications, which in term supports them with their COPD. This app is now used by COPD patients across the UK, via a prescription from their healthcare professionals. my mHealth has now developed a research app MMH-LAB1 which, in the intervention arm, includes an algorithm to assist patients with understanding their level of symptom burden according to the severity of their daily symptoms and exacerbation risk. The algorithm then analyses current patient prescribed inhaled medication against those recommended by the GOLD 2023 report and informs the patient via the MMH-LAB1 app as to whether their medication needs to be changed by their healthcare provider. This trial will explore whether the introduction of the algorithm within the MMH-LAB1 app can be used as a safe, effective and acceptable tool to assist patients to achieve optimal guideline based inhaled therapy and therefore provide greater symptom control and lowered exacerbation risk for COPD patients.
Participants will be randomised to the MMH-LAB1 app - control arm (MMH-LAB_Control_1 where participants just record COPD symptoms and medications), or to the MMH_LAB1 app - intervention arm (MMH-LAB1_Test_1 where participants record their COPD symptoms and medication plus receiving information from the algorithm, as to whether their medications are in guidance or not, and if not, be notified to visit their healthcare professional.
Przegląd badań
Szczegółowy opis
This study is an open-label randomised control trial with inbuilt pilot phase and qualitative sub-study:
Phase 1 (pilot - 50 participants): Interim futility analysis on adherence to intervention advice Phase 2 (efficacy - 746 participants (including pilot phase participants): Safety acceptability and efficacy of intervention. This includes the qualitative sub study 15-20 participants (from the 746 Phase 2 participants).
Qualitative Sub-study: Acceptability of the intervention (15-20 intervention participants)
This trial will explore whether the introduction of the treatment realignment algorithm can be used as a safe, effective and acceptable tool to assist patients to achieve optimal, guideline based inhaled therapy and therefore provide greater symptom control and lowered exacerbation risk for COPD patients. To assess effect of the intervention on patients' symptom control, including exacerbation frequency and patient wellness scores.
Main objectives
- To understand the intervention pathway in the pilot phase and to identify additional patient support mechanisms for the efficacy phase in order to maximise healthcare equality
- To assess the levels of app usage and engagement
- To assess patients' experience of using the intervention
Study Design:
Open-Label Randomised Control Trial with inbuilt pilot phase Qualitative Sub study:
Phase 1 (Pilot): Interim futility analysis on adherence to intervention advice Phase 2 (Efficacy): Safety, acceptability and efficacy of intervention Qualitative Sub-study: Acceptability of the intervention.
The research question is to explore the safety and efficacy of the treatment re-alignment algorithm as part of a digital self-management application (app) in patients with COPD.
Typ studiów
Zapisy (Szacowany)
Faza
- Faza 1
Kontakty i lokalizacje
Kontakt w sprawie studiów
- Nazwa: Trial Manager
- Numer telefonu: +44 23 8059 6920
- E-mail: mysmartcopd@soton.ac.uk
Lokalizacje studiów
-
-
England
-
Southampton, England, Zjednoczone Królestwo, SO16 6YD
- Rekrutacyjny
- University Hospital Southampton
-
Kontakt:
- Tom Wilkinson, MA Cantab MBBS PhD FRCP FERS
- Numer telefonu: 02381 205341
- E-mail: T.Wilkinson@soton.ac.uk
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
- Dorosły
- Starszy dorosły
Akceptuje zdrowych ochotników
Opis
Inclusion Criteria:
- Adult patients over 18 years of age and able to give informed consent
- A clinical diagnosis of COPD (all patients registered on the app have a confirmed diagnosis of COPD confirmed by their clinician before being prescribed the app).
- A registered and activated user of the myCOPD app
- One or more CAT questionnaire completed on the myCOPD app in the last 12 months
- One or more exacerbation form completed on the myCOPD app in the last 12 months CTU/FORM/5321 - CIP template for Clinical Investigations of Medical Devices, Version 1 14-DEC-2023 mySmartCOPD Clinical Investigation Plan v1 25-FEB-2025 Page 25 of 53
- One or more COPD medication diary completed on the myCOPD app in the last 12 months
Classified appropriately into 3 groups:
(A) Few symptoms (CAT <10, 0 or 1 moderate exacerbations) (B) Many symptoms (CAT ≥10, ≥0 or 1 moderate exacerbations) (C)Exacerbators (≥2 moderate or ≥1 severe exacerbation independent of CAT)
Exclusion Criteria:
- Cannot read or write in English as required to understand the trial materials and provide the trial data.
- Has not opted in to the research agreement via MyCOPD
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie podtrzymujące
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Komparator placebo: MMH-LAB1 Control This arm is based on the original COPD app the participants already use
Participants for this study are already users of a COPD self management app.
This arm is a replica of this app, with additional questionnaires built in
|
This app is based on a COPD self management app, which they are already using and includes an algorithm which will notify participants if there is a discrepancy between the symptoms they report onto the app and their medication regime, and informs them to approach their healthcare provider for a medication review
|
|
Eksperymentalny: MMH-LAB1 Test This arm is based on the original COPD app the participants use plus an algorithm
Participants for this study are already users of a COPD self management app.
This arm is a replica of this app, with additional questionnaires built in plus an algorithm which identifies, based on the symptoms and medication reported onto the app by the participant, whether they are on the correct medication or not.
If not, the app will generate a notification and inform the participant that they need to approach their healthcare provider and inform them of this and that they need a medication review.
|
This app is based on a COPD self management app, which they are already using and includes an algorithm which will notify participants if there is a discrepancy between the symptoms they report onto the app and their medication regime, and informs them to approach their healthcare provider for a medication review
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
To determine the safety, acceptability and efficacy of a digital treatment guidance algorithm for inhaled treatment in patients with COPD. The intention is to measure the impact of the algorithm in prompting patients to achieve optimal management, and t
Ramy czasowe: 6 months
|
Proportion (measured in %) of participants receiving guideline adherent treatment at Baseline and trial completion (Month 6).
Range 0%-100%.
|
6 months
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
To assess effect of intervention on exacerbation frequency and patient wellness scores
Ramy czasowe: 6 months
|
• Change in COPD Assessment Test (CAT) score between Baseline and trial completion (Month 6) CAT test results 0 minimal symptom impact - Best and 40 maximum symptom impact All will be described in terms of:
|
6 months
|
|
To assess effect of the intervention on patients' adherence to guideline mandated treatment
Ramy czasowe: 6 months
|
- Rate of indication of algorithm to change treatment (0 times to 150 times) • Rate if change in response to treatment change indication (0 times to 150 times) All measured via frequency and percentage and description of change. The combination of measurements will be reported as descriptive stats |
6 months
|
|
To understand the utility of the intervention pathway in the pilot phase and to identify additional patient support mechanisms for the efficacy phase in order to maximise healthcare equality
Ramy czasowe: 6 months
|
- % Patients receiving guideline adherent treatment at Baseline and trial completion (Month 6). 100% good. 0 % bad. Above described qualitatively and in terms of % and frequency |
6 months
|
|
To assess the levels of app algorithm usage and engagement
Ramy czasowe: 6 months
|
-Frequency of app engagement
Measured by frequency (numbers of participant who completed everything) % (0% of expected use bad and 100% of expected use good). This will be reported as descriptive stats. |
6 months
|
|
To understand patients' experience of using the intervention
Ramy czasowe: 3-6 months - interviews. 6 months - feedback questionnaire
|
This section relates to the qualitative sub-study and will look at the following: - Patient experience and patient and patient advocate feedback on experience of using app • Patient satisfaction Rating using the Patient Using feedback questionnaire at month 6 and qualitative interviews as part of the sub -study
This will be reported in a separate analysis document using qualitative research analysis and reporting techniques and norms |
3-6 months - interviews. 6 months - feedback questionnaire
|
|
To assess the safety of the algorithm
Ramy czasowe: 6 months
|
• Rate of algorithm inappropriately firing notifications This is data collected via MMHLAB apps and qualitatively via patient advocate.
|
6 months
|
|
To assess the change in frequency of exacerbations
Ramy czasowe: 6 months
|
Frequency of exacerbation between Baseline and trial completion (Month 6) • Frequency and percentages (for number of exacerbations) Frequency will be measured from 0-150 with 0 being optimal.
This will be reported as descriptive stats.
|
6 months
|
|
To assess the change in Quality of Life between baseline and 6 months
Ramy czasowe: 6 months
|
Change in Quality of Life.
Ratings measured using EQ-5D questionnaire between Baseline and trial completion (Month 6).
All will be described in terms of: • Mean and SD • Median and range.
Score 11111 will be classed as full health and 55555 will be classed worst health.
This will be reported as descriptive stats
|
6 months
|
Współpracownicy i badacze
Sponsor
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Szacowany)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- 355764
- AI_Award02200 (Inny numer grantu/finansowania: UK - National Institute for Health and Care Research)
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .